Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. The company aims to improve population health through innovative therapies and vaccines, leveraging both in-house capabilities and strategic collaborations. Tonix is actively engaged in addressing public health emergencies, particularly in the field of infectious diseases, including the development of vaccines for smallpox and monkeypox.
Tonix Pharmaceuticals
26 Main Street – Suite 101, Chatham, NJ 07928
What We Do
A sublingual formulation of cyclobenzaprine HCl designed for the management of fibromyalgia and acute stress disorder. It has completed two Phase III studies and is expected to file an NDA in 2H 2024.
A recombinant protein enzyme for the treatment of cocaine intoxication, currently in Phase II with Breakthrough Therapy Designation from the FDA.
A humanized monoclonal antibody directed against CD40-ligand, in development for organ transplant rejection and autoimmune disorders, currently in Phase I.
A stabilized recombinant version of Trefoil Factor 2 (TFF2) being developed for gastric and colorectal cancers, currently in preclinical stages.
A live horsepox virus vaccine candidate for the prevention of smallpox and monkeypox, currently in preclinical development.
A live attenuated modified horsepox virus vaccine designed to express the Spike protein of SARS-CoV-2, currently in preclinical development.
Services
Psychological and Cognitive Health and Performance
Drugs
Key People
News & Updates
Tonix Pharmaceuticals will be participating in the NobleCon20 Investor Conference.
Tonix Pharmaceuticals will present at the Winter 2024 Investor Summit Virtual.
Tonix Pharmaceuticals presented data on TNX-102 SL treatment effects on fibromyalgia at the ACR Convergence 2024 Annual Meeting.
Tonix Pharmaceuticals announced a poster presentation at the ACR Convergence 2024 Annual Meeting.